We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Epigenetic Markers Predict Type 2 Diabetes Patients Response to Metformin

By LabMedica International staff writers
Posted on 29 Sep 2020
Generally, metformin is the first medication prescribed for type 2 diabetes (T2D). More...
It works by lowering glucose production in the liver and improving the body's sensitivity to insulin so that the body uses insulin more effectively. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin.

About 30% of patients do not respond to metformin and between 20% and 30% experience side effects that can be intolerable Gastrointestinal side effects of metformin are observed in 10% to 15% of patients, depending on the dose, and include abdominal discomfort, anorexia, bloating, and diarrhea. Because insulin secretion is unaltered, hypoglycemia is not a side effect of metformin used as monotherapy.

An international team of clinical scientists led by those at Skåne University Hospital (Malmo, Sweden) conducted multiple epigenome-wide association studies by analyzing in the blood of drug-naïve patients who were recently diagnosed with T2D. Blood samples were collected from the All New Diabetics In Scandia (ANDIS) cohort and analyzed using Illumina's MethylationEpic array (Illumina, San Diego, CA, USA). The team sought to gauge whether differences in DNA methylation prior to treatment could predict whether individuals had changes in glycated hemoglobin (HbA1c), responded to the drug treatment, or experienced intolerance to the drug following about a year and a half of metformin treatment.

The investigators identified more than 2,500 methylation sites that were significantly associated with changes in HbA1c, a marker of blood glucose levels. In the replication cohort, 132 CpGs of these sites were validated. They additionally uncovered 7,916 methylation sites that differed between individuals with T2D who responded to metformin and individuals who did not. Of those, 601 were then validated in the ANDIS replication cohort and 329 in an additional cohorts.

In all, 33 CpG sites were associated with future metformin response in all cohorts, and in a combined meta-analysis 11 sites reached genome-wide significance. At the same time, the team found 9,676 methylation sites that differed between individuals with T2D who could tolerate metformin treatment and those who could not. In the ANDIS replication cohort, 235 CpGs were validated, and in the replication cohort, 352 CpGs were. Seven CpGs were associated with metformin in all cohorts, and in a combined meta-analysis four sites reached genome-wide significance.

The scientists generated two methylation risk scores, one of metformin response and one of metformin intolerance. For the metformin response, they bundled together the 11 sites to form a weighted methylation risk score that could differentiate between responders and non-responders with an area under the curve of between 0.80 and 0.89. Meanwhile, for metformin intolerance, they combined the four sites that reached genome-wide significance into a separate risk score that could differentiate between tolerant and intolerant individuals with an area under the curve of between 0.85 and 0.94.

The authors concludes that they could discriminate between glycemic responders/non-responders and participants tolerant/intolerant to metformin at diagnosis by measuring blood-based epigenetic markers in drug-naïve patients with T2D. This epigenetics-based tool may be further developed to help patients with T2D receive optimal therapy. The study was published on September 16, 2020 in the journal Science Translational Medicine.



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.